Literature DB >> 15610525

Endothelin-1 upregulates MCAM in melanocytes.

Catherine R Mangahas1, Gelo V dela Cruz, Robert J Schneider, Sumayah Jamal.   

Abstract

Melanoma cell adhesion molecule (MCAM) is a cell-surface adhesion molecule expressed on over 70% of metastatic melanoma cells but not expressed in normal melanocytes invivo. Protein levels of MCAM correlate with aggressive invasive behavior of melanoma cells in vitro and invivo. Here we demonstrate that endothelin-1 (ET-1) upregulates MCAM protein in primary human melanocytes. MCAM upregulation by ET-1 occurs irrespective of degree of melanocyte pigmentation and is dose-responsive. The drug BQ788 is an endothelin-B (ET(B)) receptor antagonist and inhibits upregulation of MCAM by ET-1. In addition, endothelin-3 (ET-3) and N-succinyl-[Glu9, Ala11, 15]-ET-1-1620, both selective ET(B) agonists, are potent upregulators of MCAM. These demonstrate a critical role for the ET(B) receptor in the upregulation of MCAM by ET-1 and related isoforms. MCAM mRNA abundance is also increased by ET-1 stimulation, thus the mechanism of MCAM protein upregulation may occur at the level of transcription. Our previous studies have demonstrated that ET-1 downregulates E-cadherin in melanocytes and melanoma cells. Since E-cadherin is a melanoma invasion suppressor, and MCAM is a melanoma invasion promoter, ET-1 may promote melanoma invasion and metastasis through the regulation of adhesion molecule expression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15610525     DOI: 10.1111/j.0022-202X.2004.23480.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  7 in total

1.  Loss of nuclear receptor RXRα in epidermal keratinocytes promotes the formation of Cdk4-activated invasive melanomas.

Authors:  Stephen Hyter; Gaurav Bajaj; Xiaobo Liang; Mariano Barbacid; Gitali Ganguli-Indra; Arup Kumar Indra
Journal:  Pigment Cell Melanoma Res       Date:  2010-07-09       Impact factor: 4.693

2.  A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma.

Authors:  Richard Kefford; Jane McNeil Beith; Guy Arthur Van Hazel; Michael Millward; James Marshall Trotter; David Keith Wyld; Rada Kusic; Revati Shreeniwas; Adele Morganti; Andrea Ballmer; Eleonor Segal; Oliver Nayler; Martine Clozel
Journal:  Invest New Drugs       Date:  2006-10-05       Impact factor: 3.850

3.  CD146 as a promising therapeutic target for retinal and choroidal neovascularization diseases.

Authors:  Bai Xue; Ping Wang; Wenzhen Yu; Jing Feng; Jie Li; Rulian Zhao; Zhenglin Yang; Xiyun Yan; Hongxia Duan
Journal:  Sci China Life Sci       Date:  2021-10-29       Impact factor: 10.372

Review 4.  Malignant melanoma in the 21st century: the emerging molecular landscape.

Authors:  Aleksandar Sekulic; Paul Haluska; Arlo J Miller; Josep Genebriera De Lamo; Samuel Ejadi; Jose S Pulido; Diva R Salomao; Erik C Thorland; Richard G Vile; David L Swanson; Barbara A Pockaj; Susan D Laman; Mark R Pittelkow; Svetomir N Markovic
Journal:  Mayo Clin Proc       Date:  2008-07       Impact factor: 7.616

5.  Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells.

Authors:  James B Freeman; Elin S Gray; Michael Millward; Robert Pearce; Melanie Ziman
Journal:  J Transl Med       Date:  2012-09-15       Impact factor: 5.531

6.  Structure basis for AA98 inhibition on the activation of endothelial cells mediated by CD146.

Authors:  Xuehui Chen; Huiwen Yan; Dan Liu; Qingji Xu; Hongxia Duan; Jing Feng; Xiyun Yan; Can Xie
Journal:  iScience       Date:  2021-04-14

7.  Knockdown of CD146 promotes endothelial-to-mesenchymal transition via Wnt/β-catenin pathway.

Authors:  Zhao-Yu Zhang; Chao Zhai; Xue-Yuan Yang; Hai-Bing Li; Li-Ling Wu; Li Li
Journal:  PLoS One       Date:  2022-08-24       Impact factor: 3.752

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.